BACKGROUND & AIMS: Controversy exists as to whether patients with inflammatory bowel disease have an underlying immunodeficiency. We have focused on a murine model of the Wiskott-Aldrich syndrome, an immunodeficiency in which autoimmunity can manifest in the form of an inflammatory bowel disease-like illness. Wiskott-Aldrich syndrome protein (WASP) deficiency in mice results in similar clinical features. Herein, we characterized the colitis in WASP-deficient mice. METHODS: WASP-deficient mice were followed clinically and histologically. Immunologic studies were performed to determine the pathogenic cell population(s), the predominant cytokine expression pattern, and the role of cytokine(s) in colitis pathogenesis. RESULTS: All WASP-deficient mice develop colitis by 6 months of age. Lymphocytes are required for disease induction, and CD4(+) T cells from WASP-deficient mice are sufficient to induce disease in lymphocyte-deficient hosts. Lamina propria preparations from WASP-deficient mice demonstrated elevations in interferon-gamma, interleukin (IL)-4, and IL-13 levels but decreased IL-6 and no difference in IL-17 expression in comparison with wild-type controls. Treatment with neutralizing antibody to IL-4, but not to interferon-gamma, abrogated colitis development. However, mice deficient in both WASP and IL-4 showed no difference in histologic colitis scores at 24 weeks of age compared with WASP-deficient mice. CONCLUSIONS: These results demonstrate a critical role for lymphocytes and a relative T helper 2 cytokine predominance in the colitis associated with WASP-deficient mice. This is the only model of colitis with elevated T helper 2 cytokines and aberrant natural regulatory T cell function and is unique in having a human disease counterpart with similar defects.
BACKGROUND & AIMS: Controversy exists as to whether patients with inflammatory bowel disease have an underlying immunodeficiency. We have focused on a murine model of the Wiskott-Aldrich syndrome, an immunodeficiency in which autoimmunity can manifest in the form of an inflammatory bowel disease-like illness. Wiskott-Aldrich syndrome protein (WASP) deficiency in mice results in similar clinical features. Herein, we characterized the colitis in WASP-deficient mice. METHODS:WASP-deficient mice were followed clinically and histologically. Immunologic studies were performed to determine the pathogenic cell population(s), the predominant cytokine expression pattern, and the role of cytokine(s) in colitis pathogenesis. RESULTS: All WASP-deficient mice develop colitis by 6 months of age. Lymphocytes are required for disease induction, and CD4(+) T cells from WASP-deficient mice are sufficient to induce disease in lymphocyte-deficient hosts. Lamina propria preparations from WASP-deficient mice demonstrated elevations in interferon-gamma, interleukin (IL)-4, and IL-13 levels but decreased IL-6 and no difference in IL-17 expression in comparison with wild-type controls. Treatment with neutralizing antibody to IL-4, but not to interferon-gamma, abrogated colitis development. However, mice deficient in both WASP and IL-4 showed no difference in histologic colitis scores at 24 weeks of age compared with WASP-deficient mice. CONCLUSIONS: These results demonstrate a critical role for lymphocytes and a relative T helper 2 cytokine predominance in the colitis associated with WASP-deficient mice. This is the only model of colitis with elevated T helper 2 cytokines and aberrant natural regulatory T cell function and is unique in having a human disease counterpart with similar defects.
Authors: Michel H Maillard; Vinicius Cotta-de-Almeida; Fuminao Takeshima; Deanna D Nguyen; Pierre Michetti; Cathryn Nagler; Atul K Bhan; Scott B Snapper Journal: J Exp Med Date: 2007-02-12 Impact factor: 14.307
Authors: Marika C Kullberg; Dragana Jankovic; Carl G Feng; Sophie Hue; Peter L Gorelick; Brent S McKenzie; Daniel J Cua; Fiona Powrie; Allen W Cheever; Kevin J Maloy; Alan Sher Journal: J Exp Med Date: 2006-10-09 Impact factor: 14.307
Authors: Nuzhat Iqbal; James R Oliver; Frederic H Wagner; Audrey S Lazenby; Charles O Elson; Casey T Weaver Journal: J Exp Med Date: 2002-01-07 Impact factor: 14.307
Authors: J Zhang; A Shehabeldin; L A da Cruz; J Butler; A K Somani; M McGavin; I Kozieradzki; A O dos Santos; A Nagy; S Grinstein; J M Penninger; K A Siminovitch Journal: J Exp Med Date: 1999-11-01 Impact factor: 14.307
Authors: Nikolay P Nikolov; Masaki Shimizu; Sophia Cleland; Daniel Bailey; Joseph Aoki; Ted Strom; Pamela L Schwartzberg; Fabio Candotti; Richard M Siegel Journal: Blood Date: 2010-05-10 Impact factor: 22.113
Authors: Sundaram Ramasamy; Deanna D Nguyen; Michelle A Eston; Sayeda Nasrin Alam; Angela K Moss; Farzad Ebrahimi; Brishti Biswas; Golam Mostafa; Kathryn T Chen; Kanakaraju Kaliannan; Halim Yammine; Sonoko Narisawa; José Luis Millán; H Shaw Warren; Elizabeth L Hohmann; Emiko Mizoguchi; Hans-Christian Reinecker; Atul K Bhan; Scott B Snapper; Madhu S Malo; Richard A Hodin Journal: Inflamm Bowel Dis Date: 2011-02 Impact factor: 5.325
Authors: Michael J Rosen; Rebekah Karns; Jefferson E Vallance; Ramona Bezold; Amanda Waddell; Margaret H Collins; Yael Haberman; Phillip Minar; Robert N Baldassano; Jeffrey S Hyams; Susan S Baker; Richard Kellermayer; Joshua D Noe; Anne M Griffiths; Joel R Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Michael D Kappelman; James Markowitz; Dedrick E Moulton; Neal S Leleiko; Thomas D Walters; Subra Kugathasan; Keith T Wilson; Simon P Hogan; Lee A Denson Journal: Gastroenterology Date: 2017-01-26 Impact factor: 22.682
Authors: Claire Billerey-Larmonier; Jennifer K Uno; Nicolas Larmonier; Anna J Midura; Barbara Timmermann; Fayez K Ghishan; Pawel R Kiela Journal: Inflamm Bowel Dis Date: 2008-06 Impact factor: 5.325